While Japan has now granted its first emergency approval to Shionogi’s COVID-19 pill Xocova (ensitrelvir), the drug failed to win a unanimous vote by advisory panels, with skepticism lingering over its actual efficacy. To prep for the next emergency, which…
HOME > ORGANIZATION
ORGANIZATION
- Industry, Academia Launch Project to Raise Public Awareness of COPD
November 1, 2012
- Officials from MOPH of Thailand Receive Quality Control Training: JPMA’s Int’l Cooperation Activities
October 26, 2012
- 1st Graduates Under 6-Year Pharmacy Education System Push Up Percentage of Qualified Pharmacists among Applicants for This Year’s MR Exam: MREAC
October 24, 2012
- Nearly 1,200 Municipalities Cover Full Cost of HPV Vaccinations: Expert Organization Survey
October 23, 2012
- Former Benesis GMP Violation: Ueda Vows to “Root Out” Problems in JBPO
October 19, 2012
- JBPO Looks to Boost Japan’s Self-Sufficiency Ratio of Plasma Derivatives, Mulls Further Integration: Pres. Ueda
October 18, 2012
- Mr Kaiya of Kyokai Kenpo Optimistic About Reaching 30% Generic Drug Use Target
October 18, 2012
- Sino-Japanese Pharmaceutical Exchange Symposium to Be Postponed at Request of China: OPMA
October 15, 2012
- OPMA Temporarily Freezes JBPO’s Appointment as Its Board Member, FPMAJ’s Member of Board of Trustees
October 15, 2012
- Permanent New Drug Premium, Expanded R&D Tax Credits Needed to Encourage Innovation and Investment: FPMAJ Chairman Naito
October 12, 2012
- Price Gap between Long-Listed Products, Generics Necessary: FPMAJ Chairman Naito
October 11, 2012
- President Teshirogi of JPMA Stresses Need for Asian Countries to Cooperate in Drug Discovery
October 11, 2012
- Proposal to Unify Basic Dispensing Fees Could Be Taken Up Again: JPA Vice President Miura
October 10, 2012
- Life Science Budget in Japan Lacks Absolute Amount: JPMA President Teshirogi
October 10, 2012
- “Industry Also Needs to Consider” Distribution of Drug Expenditure: Former Administrative Vice Minister of Health Erikawa
October 5, 2012
- Enterprise Integration Has Not Yet Advanced among Drugmakers in Japan: Former JFTC Chairman Takeshima
September 27, 2012
- MHLW to Announce 14 New Examples of Approved Off-Label Drug Use Based on 1980 Notification in Near Future
September 26, 2012
- Risk for 7 Main Diseases Increases at Age 63: Anti-Aging Laboratory
September 25, 2012
- JPA Issues Notice on Prohibition of Dispensing Point Services, “Not Intended as Transitional Measure”
September 25, 2012
- Wholesale Industry FTC’s Liaison Conference on Ending Provision of Free Benefits and Labor to Hold 1st Meeting in October
September 25, 2012
ページ
As the year 2022 draws to a close, what are managers thinking at the world’s leading pharmaceutical companies and medical device companies? We surveyed 86 managers at these companies to find out what’s on their minds.For many managers, a common…
A Japanese reimbursement policy panel on November 16 saw a continued scuffle between members representing healthcare providers and payers over…
Deloitte Tohmatsu Consulting proposed three drug pricing schemes designed to trigger the consolidation of generic makers on October 27, offering…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…